Recombinant Full Length Human TGFBR2 Protein, C-Flag-tagged

• Cat.No.: TGFBR2-909HFL
• Product Overview: Recombinant Full Length Human TGFBR2 Protein, fused to Flag-tag at C-terminus, was expressed in Mammalian cells.

Specification

• Description: The protein encoded by this gene is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of genes related to cell proliferation, cell cycle arrest, wound healing, immunosuppression, and tumorigenesis. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized.
• Source: Mammalian cells
• Species: Human
• Tag: Flag
• Form: 25 mM Tris HCl, pH 7.3, 100 mM glycine, 10% glycerol.
• Molecular Mass: 62 kDa
• AA Sequence: MGRGLLRGLWPLHIVLWTRIASTIP PHVQKSVNNDMIVTDNNGAVKFPQL CKFCDVRFSTCDNQKSCMSN CSITSICEKPQEVCVAVWRKNDENI TLETVCHDPKLPYHDFILEDAASPK CIMKEKKKPGETFFMCSCSS DECNDNIIFSEEYNTSNPDLLLVIF QVTGISLLPPLGVAISVIIIFYCYR VNRQQKLSSTWETGKTRKLM EFSEHCAIILEDDRSDISSTCANNI NHNTELLPIELDTLVGKGRFAEVYK AKLKQNTSEQFETVAVKIFP YEEYASWKTEKDIFSDINLKHENIL QFLTAEERKTELGKQYWLITAFHAK GNLQEYLTRHVISWEDLRKL GSSLARGIAHLHSDHTPCGRPKMPI VHRDLKSSNILVKNDLTCCLCDFGL SLRLDPTLSVDDLANSGQVG TARYMAPEVLESRMNLENVESFKQT DVYSMALVLWEMTSRCNAVGEVKDY EPPFGSKVREHPCVESMKDN VLRDRGRPEIPSFWLNHQGIQMVCE TLTECWDHDPEARLTAQCVAERFSE LEHLDRLSGRSCSEEKIPED
  GSLNTTKSGPTRTRRLEQKLISEED LAANDILDYKDDDDKV
• Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining.
• Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles.
• Storage: Store at -80 centigrade.
• Concentration: >50 ug/mL as determined by microplate BCA method.
• Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps.
• Protein Families: Druggable Genome, Protein Kinase, Transmembrane
• Protein Pathways: Adherens junction, Chronic myeloid leukemia, Colorectal cancer, Cytokine-cytokine receptor interaction, Endocytosis, MAPK signaling pathway, Pancreatic cancer, Pathways in cancer, TGF-beta signaling pathway

Gene Information

• Gene Name: TGFBR2 transforming growth factor beta receptor 2 [ Homo sapiens (human) ]
• Official Symbol: TGFBR2
• Synonyms: AAT3; FAA3; LDS2; MFS2; RIIC; LDS1B; LDS2B; TAAD2; TBRII; TBR-ii; TGFR-2; tbetaR-II; TGFbeta-RII
• Gene ID: 7048
• mRNA Refseq: NM_003242.6
• Protein Refseq: NP_003233.4
• MIM: 190182
• UniProt ID: P37173

Reviews

04/14/2023

TGFBR2 protein's remarkable performance in ELISA and protein electron microscopy structure analysis positions it as a valuable tool in various fields, including cardiovascular research, developmental biology, and molecular medicine.

12/13/2022

TGFBR2 protein's utility extends to protein electron microscopy structure analysis, where it plays a crucial role in investigating the detailed architecture and conformational changes of proteins.

06/25/2021

TGFBR2 protein is highly recommended for use in various research applications, including ELISA and protein electron microscopy structure analysis.

Q&As

How is TGFBR2 linked to autoimmune diseases?

Dysregulation of TGF-beta signaling, including TGFBR2, has been associated with autoimmune diseases. Understanding these pathways may provide insights into developing targeted therapies.

Are there clinical trials targeting TGFBR2?

Yes, there are ongoing clinical trials exploring the modulation of TGFBR2 for various conditions, including cancer and fibrotic diseases.

How does TGFBR2 affect cardiovascular health?

TGFBR2 is involved in cardiovascular development and homeostasis. Dysregulation can contribute to conditions like aortic aneurysms and other cardiovascular diseases.

Is TGFBR2 involved in neurological disorders?

Some studies suggest a potential link between TGFBR2 and neurological disorders. Further research is ongoing to understand its role in conditions like Alzheimer's and Parkinson's disease.

Can TGFBR2 be a therapeutic target for fibrotic diseases?

Yes, TGFBR2 is implicated in fibrosis, and targeting it may offer therapeutic options for diseases characterized by excessive tissue scarring.